Vault-13

Frazier Life Sciences Management, L.P.

PALO ALTO, CA · CIK 1892134 · 13F filing filed 2024-08-15

SEC-registered investment adviser since 2021 · limited partnership

As an employer

Where they work

people there (dot area)number not reportedmain officeHover or tap a dot. Australian and UK companies are placed at their business or registered address, with their staff across the whole country.

Offices

From Form ADV: the main office and the other offices where it does advisory work (at most the 25 largest), with the people doing investment work at each. “About” is worked out: the firm's investment staff less its other offices. Each city links to the other managers there.

CityCountryPeople
Palo Alto, CA (main office)United States United Statesabout 44
San Diego, CAUnited States United States3

Map: places from GeoNames (CC BY 4.0), outlines from Natural Earth.

$2.1bn reported value -9.8% vs Q1 2024
49positions
62.0%in top 10
8 new 13 added 4 reduced 9 sold out vs Q1 2024

Holdings, Q2 2024

The small lines show how much was held over the last 4 quarters (adjusted for stock splits).

#SecurityTickerShares Value% of portfolioChangeShares change
1 NEWAMSTERDAM PHARMA COMPANY ORDINARY SHARES NAMS NAMS 12,226,943 $234.9m10.99% 10.99% UnchangedShares held: Q3 2023 12.1m, Q4 2023 12.1m, Q1 2024 12.2m, Q2 2024 12.2m
2 MIRUM PHARMACEUTICALS INC COM MIRM MIRM 6,495,392 $222.1m10.39% 10.39% UnchangedShares held: Q3 2023 6.5m, Q4 2023 6.5m, Q1 2024 6.5m, Q2 2024 6.5m
3 KRYSTAL BIOTECH INC COM KRYS KRYS 988,460 $181.5m8.49% 8.49% UnchangedShares held: Q3 2023 988.5k, Q4 2023 988.5k, Q1 2024 988.5k, Q2 2024 988.5k
4 HILLEVAX INC COM COM 10,617,062 $153.5m7.18% 7.18% AddedShares held: Q3 2023 9.8m, Q4 2023 9.8m, Q1 2024 9.8m, Q2 2024 10.6m +835.6k +835,590 8.5%
5 PHATHOM PHARMACEUTICALS INC COM PHAT PHAT 10,109,279 $104.1m4.87% 4.87% UnchangedShares held: Q3 2023 10.1m, Q4 2023 10.1m, Q1 2024 10.1m, Q2 2024 10.1m
6 RHYTHM PHARMACEUTICALS INC COM RYTM RYTM 2,371,304 $97.4m4.55% 4.55% AddedShares held: Q3 2023 2.4m, Q4 2023 2.4m, Q1 2024 2.2m, Q2 2024 2.4m +181.1k +181,125 8.3%
7 BRIDGEBIO PHARMA INC COM BBIO BBIO 3,632,604 $92.0m4.30% 4.30% AddedShares held: Q3 2023 2.7m, Q4 2023 2.7m, Q1 2024 3.4m, Q2 2024 3.6m +217.0k +217,000 6.3%
8 ARCUTIS BIOTHERAPEUTICS INC COM ARQT ARQT 8,785,284 $81.7m3.82% 3.82% UnchangedShares held: Q3 2023 8.7m, Q4 2023 8.8m, Q1 2024 8.8m, Q2 2024 8.8m
9 DISC MEDICINE INC COM IRON IRON 1,754,834 $79.1m3.70% 3.70% AddedShares held: Q3 2023 655.0k, Q4 2023 785.0k, Q1 2024 785.0k, Q2 2024 1.8m +969.8k +969,834 123.5%
10 VAXCYTE INC COM PCVX PCVX 1,039,405 $78.5m3.67% 3.67% ReducedShares held: Q3 2023 1.2m, Q4 2023 1.2m, Q1 2024 1.1m, Q2 2024 1.0m -100.0k -100,000 -8.8%
11 EDGEWISE THERAPEUTICS INC COM EWTX EWTX 3,731,067 $67.2m3.14% 3.14% AddedShares held: Q3 2023 849.0k, Q4 2023 2.7m, Q1 2024 3.3m, Q2 2024 3.7m +427.5k +427,500 12.9%
12 ANAPTYSBIO INC COM ANAB ANAB 2,165,591 $54.3m2.54% 2.54% AddedShares held: Q3 2023 899.7k, Q4 2023 899.7k, Q1 2024 899.7k, Q2 2024 2.2m +1.3m +1,265,891 140.7%
13 VERONA PHARMA PLC SPONSORED ADS VRNA VRNA 3,314,349 $47.9m2.24% 2.24% AddedShares held: Q3 2023 3.0m, Q4 2023 3.0m, Q1 2024 3.0m, Q2 2024 3.3m +300.0k +300,000 9.9%
14 KALVISTA PHARMACEUTICALS INC COM KALV KALV 3,687,867 $43.4m2.03% 2.03% UnchangedShares held: Q3 2023 3.2m, Q4 2023 3.6m, Q1 2024 3.7m, Q2 2024 3.7m
15 TARSUS PHARMACEUTICALS INC COM TARS TARS 1,587,527 $43.1m2.02% 2.02% ReducedShares held: Q3 2023 1.8m, Q4 2023 1.8m, Q1 2024 1.8m, Q2 2024 1.6m -200.0k -200,000 -11.2%
16 REVOLUTION MEDICINES INC COM RVMD RVMD 997,455 $38.7m1.81% 1.81% UnchangedShares held: Q3 2023 997.5k, Q4 2023 997.5k, Q1 2024 997.5k, Q2 2024 997.5k
17 ERASCA INC COM ERAS ERAS 16,216,216 $38.3m1.79% 1.79% NewShares held: Q3 2023 0, Q4 2023 0, Q1 2024 0, Q2 2024 16.2m
18 AGIOS PHARMACEUTICALS INC COM AGIO AGIO 871,974 $37.6m1.76% 1.76% AddedShares held: Q3 2023 292.0k, Q4 2023 523.2k, Q1 2024 523.2k, Q2 2024 872.0k +348.8k +348,808 66.7%
19 SOLENO THERAPEUTICS INC COM SLNO SLNO 875,667 $35.7m1.67% 1.67% UnchangedShares held: Q3 2023 464.9k, Q4 2023 464.9k, Q1 2024 875.7k, Q2 2024 875.7k
20 ROCKET PHARMACEUTICALS INC COM RCKT RCKT 1,561,230 $33.6m1.57% 1.57% UnchangedShares held: Q3 2023 1.4m, Q4 2023 1.5m, Q1 2024 1.6m, Q2 2024 1.6m
21 SAVARA INC COM SVRA SVRA 8,157,385 $32.9m1.54% 1.54% AddedShares held: Q3 2023 4.0m, Q4 2023 4.0m, Q1 2024 4.0m, Q2 2024 8.2m +4.2m +4,157,385 103.9%
22 ORIC PHARMACEUTICALS INC COM ORIC ORIC 4,142,855 $29.3m1.37% 1.37% UnchangedShares held: Q3 2023 2.1m, Q4 2023 2.1m, Q1 2024 4.1m, Q2 2024 4.1m
23 CG ONCOLOGY INC COM CGON CGON 770,000 $24.3m1.14% 1.14% UnchangedShares held: Q3 2023 0, Q4 2023 0, Q1 2024 770.0k, Q2 2024 770.0k
24 PEPGEN INC COM PEPG PEPG 1,502,788 $24.0m1.12% 1.12% UnchangedShares held: Q3 2023 0, Q4 2023 0, Q1 2024 1.5m, Q2 2024 1.5m
25 MERUS N V COM MRUS MRUS 373,100 $22.1m1.03% 1.03% ReducedShares held: Q3 2023 746.5k, Q4 2023 746.5k, Q1 2024 746.5k, Q2 2024 373.1k -373.4k -373,379 -50.0%
26 TREVI THERAPEUTICS INC COM TRVI TRVI 7,381,090 $22.0m1.03% 1.03% UnchangedShares held: Q3 2023 6.9m, Q4 2023 7.4m, Q1 2024 7.4m, Q2 2024 7.4m
27 SILENCE THERAPEUTICS PLC ADS SLN SLN 1,148,591 $21.8m1.02% 1.02% UnchangedShares held: Q3 2023 881.2k, Q4 2023 881.2k, Q1 2024 1.1m, Q2 2024 1.1m
28 ULTRAGENYX PHARMACEUTICAL IN COM RARE RARE 425,000 $17.5m0.82% 0.82% NewShares held: Q3 2023 0, Q4 2023 0, Q1 2024 0, Q2 2024 425.0k
29 AUTOLUS THERAPEUTICS PLC SPON ADS AUTL AUTL 4,623,324 $16.1m0.75% 0.75% UnchangedShares held: Q3 2023 3.7m, Q4 2023 3.7m, Q1 2024 4.6m, Q2 2024 4.6m
30 CEREVEL THERAPEUTICS HLDNG I COM CERE CERE 393,000 $16.1m0.75% 0.75% UnchangedShares held: Q3 2023 393.0k, Q4 2023 393.0k, Q1 2024 393.0k, Q2 2024 393.0k
31 MEREO BIOPHARMA GROUP PLC SPON ADS MREO MREO 4,401,371 $15.8m0.74% 0.74% NewShares held: Q3 2023 0, Q4 2023 0, Q1 2024 0, Q2 2024 4.4m
32 IMMATICS N.V SHS IMTX IMTX 1,152,456 $13.4m0.63% 0.63% NewShares held: Q3 2023 0, Q4 2023 0, Q1 2024 0, Q2 2024 1.2m
33 TYRA BIOSCIENCES INC COM TYRA TYRA 832,220 $13.3m0.62% 0.62% UnchangedShares held: Q3 2023 1.0m, Q4 2023 1.0m, Q1 2024 832.2k, Q2 2024 832.2k
34 MACROGENICS INC COM MGNX MGNX 3,010,727 $12.8m0.60% 0.60% AddedShares held: Q3 2023 1.8m, Q4 2023 2.4m, Q1 2024 2.5m, Q2 2024 3.0m +539.0k +539,023 21.8%
35 APPLIED THERAPEUTICS INC COM APLT APLT 2,286,135 $10.7m0.50% 0.50% AddedShares held: Q3 2023 0, Q4 2023 0, Q1 2024 2.0m, Q2 2024 2.3m +333.3k +333,278 17.1%
36 PUMA BIOTECHNOLOGY INC COM PBYI PBYI 3,062,558 $10.0m0.47% 0.47% AddedShares held: Q3 2023 0, Q4 2023 0, Q1 2024 2.8m, Q2 2024 3.1m +246.3k +246,264 8.7%
37 89BIO INC COM ETNB ETNB 1,000,000 $8.0m0.37% 0.37% UnchangedShares held: Q3 2023 0, Q4 2023 2.0m, Q1 2024 1.0m, Q2 2024 1.0m
38 ELEVATION ONCOLOGY INC COM COM 2,958,579 $8.0m0.37% 0.37% NewShares held: Q3 2023 0, Q4 2023 0, Q1 2024 0, Q2 2024 3.0m
39 COGENT BIOSCIENCES INC COM COGT COGT 936,576 $7.9m0.37% 0.37% UnchangedShares held: Q3 2023 1.5m, Q4 2023 2.0m, Q1 2024 936.6k, Q2 2024 936.6k
40 ACADIA PHARMACEUTICALS INC COM ACAD ACAD 470,338 $7.6m0.36% 0.36% UnchangedShares held: Q3 2023 630.9k, Q4 2023 730.9k, Q1 2024 470.3k, Q2 2024 470.3k
41 ARVINAS INC COM ARVN ARVN 285,331 $7.6m0.36% 0.36% UnchangedShares held: Q3 2023 285.3k, Q4 2023 285.3k, Q1 2024 285.3k, Q2 2024 285.3k
42 ADVERUM BIOTECHNOLOGIES INC COM NEW ADVM ADVM 1,069,244 $7.3m0.34% 0.34% NewShares held: Q3 2023 0, Q4 2023 0, Q1 2024 0, Q2 2024 1.1m
43 ALLOGENE THERAPEUTICS INC COM ALLO ALLO 2,867,750 $6.7m0.31% 0.31% UnchangedShares held: Q3 2023 0, Q4 2023 0, Q1 2024 2.9m, Q2 2024 2.9m
44 AN2 THERAPEUTICS INC COM ANTX ANTX 2,088,889 $4.5m0.21% 0.21% AddedShares held: Q3 2023 1.4m, Q4 2023 1.4m, Q1 2024 1.4m, Q2 2024 2.1m +700.0k +700,000 50.4%
45 NEWAMSTERDAM PHARMA COMPANY *W EXP 11/22/202 NAMSW NAMSW 500,333 $4.4m0.20% 0.20% UnchangedShares held: Q3 2023 500.3k, Q4 2023 500.3k, Q1 2024 500.3k, Q2 2024 500.3k
46 DESIGN THERAPEUTICS INC COM DSGN DSGN 1,195,179 $4.0m0.19% 0.19% NewShares held: Q3 2023 0, Q4 2023 0, Q1 2024 0, Q2 2024 1.2m
47 IMMUNOCORE HLDGS PLC ADS IMCR IMCR 108,762 $3.7m0.17% 0.17% NewShares held: Q3 2023 0, Q4 2023 0, Q1 2024 0, Q2 2024 108.8k
48 METAGENOMI INC COM MGX MGX 245,692 $1.0m0.05% 0.05% ReducedShares held: Q3 2023 0, Q4 2023 0, Q1 2024 279.0k, Q2 2024 245.7k -33.3k -33,333 -11.9%
49 ACLARIS THERAPEUTICS INC COM ACRS ACRS 264,377 $290.8k0.01% 0.01% UnchangedShares held: Q3 2023 264.4k, Q4 2023 264.4k, Q1 2024 264.4k, Q2 2024 264.4k

Sold out since Q1 2024

SecurityTickerShares held beforeValue then
ALPINE IMMUNE SCIENCES INC NVLS NVLS 3,131,008 $124.1m3.1m shares
APELLIS PHARMACEUTICALS INC APLS APLS 885,165 $52.0m885.2k shares
AEROVATE THERAPEUTICS INC 1,204,867 $35.6m1.2m shares
STRUCTURE THERAPEUTICS INC GPCR GPCR 629,194 $27.0m629.2k shares
DECIPHERA PHARMACEUTICALS IN DCPH DCPH 1,455,837 $22.9m1.5m shares
ADVERUM BIOTECHNOLOGIES INC 1,069,244 $15.1m1.1m shares
INTELLIA THERAPEUTICS INC NTLA NTLA 203,684 $5.6m203.7k shares
GRITSTONE BIO INC GRTS GRTS 1,030,878 $2.6m1.0m shares
BLUEBIRD BIO INC 1,709,907 $2.2m1.7m shares